Thelansis

Cannabis Use Disorder Market Outlook Thelansis’s “Cannabis Use Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cannabis Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? ...

  Cannabis Use Disorder Market Outlook Thelansis’s “Cannabis Use Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cannabis Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Cannabis Use Disorder Overview Cannabis as a Schedule I drug is classified by the FDA. The usage of cannabis exhibits variations across different demographic groups. Tetrahydrocannabinol (THC) serves as the primary compound responsible for the reinforcing effects of marijuana. Although the striatal dopamine system typically plays a role in substances of abuse, such as alcohol and opioids, current meta-analyses lack sufficient evidence to s...

  Cannabis as a Schedule I drug is classified by the FDA. The usage of cannabis exhibits variations across different demographic groups. Tetrahydrocannabinol (THC) serves as the primary compound responsible for the reinforcing effects of marijuana. Although the striatal dopamine system typically plays a role in substances of abuse, such as alcohol and opioids, current meta-analyses lack sufficient evidence to support a similar conclusion regarding cannabis. The Diagnostic and Statistical Manual of Mental Disorders (DSM–5) has updated the criteria for cannabis use disorder, delineating nine pathological patterns categorized under impaired control, social impairment, risky behavior, or physiological adaptation. It is focused on cannabis misuse and its associated elements, including states of intoxication, withdrawal, and cannabis use disorder. Moreover, dopamine receptors may not be directly involved. The primary objective is to enhance the overall function...